Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria
Funding
Conflicts of Interest
References
- Finegold, S.M. Anaerobic infections in humans: An overview. Anaerobe 1995, 1, 3. [Google Scholar] [CrossRef]
- Brook, I.; Wexler, H.M.; Goldstein, E.J.C. Antianaerobic antimicrobials: Spectrum and susceptibility testing. Clin. Microbiol. Rev. 2013, 26, 526. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hecht, D.W. Prevalence of antibiotic resistance in anaerobic bacteria: Worrisome developments. Clin. Infect. Dis. 2004, 39, 92. [Google Scholar] [CrossRef] [PubMed]
- Karlowsky, J.A.; Walkty, A.J.; Adam, H.J.; Baxter, M.R.; Hoban, D.J.; Zhanel, G.G. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010–2011: CANWARD surveillance study. Antimicrob. Agents Chemother. 2012, 56, 1247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Snydman, D.R.; Jacobus, N.V.; McDermott, L.A.; Golan, Y.; Goldstein, E.J.; Harrell, L.; Jenkins, S.; Newton, D.; Pierson, C.; Rosenblatt, J.; et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009. Anaerobe 2011, 17, 147. [Google Scholar] [CrossRef] [PubMed]
- Boyanova, L.; Kolarov, R.; Mitov, I. Recent evolution of antibiotic resistance in the anaerobes as compared to previous decades. Anaerobe 2015, 31, 4. [Google Scholar] [CrossRef] [PubMed]
- Cobo, F.; Rodríguez-Granger, J.; Pérez-Zapata, I.; Sampedro, A.; Aliaga, L.; Navarro-Marí, J.M. Antimicrobial susceptibility and clinical findings of significant anaerobic bacteria in southern Spain. Anaerobe 2019, 59, 49. [Google Scholar] [CrossRef] [PubMed]
- Cobo, F.; Rodríguez-Granger, J.; Sampedro, A.; Navarro-Marí, J.M. Infected breast cyst due to Prevotella buccae resistant to metronidazole. Anaerobe 2017, 48, 177. [Google Scholar] [CrossRef] [PubMed]
- Shilnikova, I.I.; Dmitrieva, N.V. Evaluation of antibiotic susceptibility of Bacteroides, Prevotella and Fusobacterium species isolated from patients of the NN Blokhin cancer research center, Moscow, Russia. Anaerobe 2015, 31, 15. [Google Scholar] [CrossRef] [PubMed]
- Cobo, F.; Sadyrbaeva-Dolgova, S.; Navarro-Marí, J.M. Different breakpoints interpretation yielded distinct resistance rates to moxifloxacin of clinically significant anaerobic bacteria. Anaerobe 2021, 72, 102471. [Google Scholar] [CrossRef] [PubMed]
- Cobo, F.; Rodríguez-Granger, J.; Sampedro, A.; Navarro-Marí, J.M. Peritoneal infection due to Peptoniphilus harei in a patient with intestinal occlusion. Anaerobe 2017, 44, 126. [Google Scholar] [CrossRef] [PubMed]
- Zerrouki, H.; Rebiahi, S.A.; Elhabiri, Y.; Fatmi, A.; Baron, S.A.; Pagnier, I.; Diene, S.M.; Rolain, J.M. Prevalence and antimicrobial resistance of Paeniclostridium sordellii in hospital settings. Antibiotics 2022, 11, 38. [Google Scholar] [CrossRef] [PubMed]
- Baquer, F.; Sawan, A.A.; Auzou, M.; Grillon, A.; Jaulhac, B.; Joint-Lambert, O.; Boyer, P.H. Broth microdiluton and gradient diffusion strips vs. reference agar dilution method: First evaluation for Clostridiales species antimicrobial susceptibility testing. Antibiotics 2021, 10, 975. [Google Scholar] [CrossRef] [PubMed]
- Valdezate, S.; Cobo, F.; Monzón, S.; Medina-Pascual, M.J.; Zaballos, A.; Cuesta, I.; Pino-Rosa, S.; Villalón, P. Genomic background and phylogeny of cfiA-positive Bacteroides fragilis strains resistant to meropenem-EDTA. Antibiotics 2021, 10, 304. [Google Scholar] [CrossRef] [PubMed]
- Strohäker, J.; Bareib, S.; Nadalin, S.; Königsrainer, A.; Ladurner, R.; Meier, A. The prevalence and clinical significance of anaerobic bacteria in major liver resection. Antibiotics 2021, 10, 139. [Google Scholar] [CrossRef] [PubMed]
- Strohäker, J.; Wiegand, L.; Beltzer, C.; Königsrainer, A.; Ladurner, R.; Meier, A. Clinical presentation and incidence of anaerobic bacteria in surgically treated biliary tract infections and cholecystitis. Antibiotics 2021, 10, 71. [Google Scholar] [CrossRef] [PubMed]
- Cobo, F.; Guillot, V.; Navarro-Marí, J.M. Breast abscesses caused by anaerobic microorganisms: Clinical and microbiological characteristics. Antibiotics 2020, 9, 341. [Google Scholar] [CrossRef] [PubMed]
- Cobo, F.; Borrego, J.; Gómez, E.; Casanovas, I.; Calatrava, E.; Foronda, C.; Navarro-Marí, J.M. Clinical findings and antimicrobial susceptibility of anaerobic bacteria isolated in bloodstream infections. Antibiotics 2020, 9, 345. [Google Scholar] [CrossRef] [PubMed]
- Kaeuffer, C.; Ruge, T.; Diancourt, L.; Romain, B.; Ruch, Y.; Jaulhac, B.; Boyer, P.H. First case of bacteraemia due to carbapenem-resistant Bacteroides faecis. Antibiotics 2021, 10, 319. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cobo, F. Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria. Antibiotics 2022, 11, 351. https://doi.org/10.3390/antibiotics11030351
Cobo F. Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria. Antibiotics. 2022; 11(3):351. https://doi.org/10.3390/antibiotics11030351
Chicago/Turabian StyleCobo, Fernando. 2022. "Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria" Antibiotics 11, no. 3: 351. https://doi.org/10.3390/antibiotics11030351
APA StyleCobo, F. (2022). Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria. Antibiotics, 11(3), 351. https://doi.org/10.3390/antibiotics11030351